Articles By Estel Grace Masangkay

  1. Pfizer To Buy InnoPharma, Acquires Injectables Portfolio 7/17/2014
    Pfizer announced that it has agreed to acquire privately-held pharmaceutical development firm InnoPharma.
  2. GSK, Codexis Announce $25M Tech And License Partnership 7/17/2014
    Biocatalyst developer Codexis announced that it has signed into a platform technology license agreement with pharmaceutical firm GlaxoSmithKline.
  3. EU Launches Initiative To Fast Track Next Gen Drugs 7/14/2014
    The second Innovative Medicines Initiative (IMI 2) has been launched in Europe with the aim of fast-tracking development of next generation drugs, particularly those targeting unmet medical needs. The 3.3 billion euro IMI 2 Strategic Research Agenda will also promote quicker patient access to new drugs.
  4. Regeneron And Sanofi Post Positive Phase 2B Data For Dupilumab In AD 7/11/2014
    Regeneron Pharmaceuticals and its partner Sanofi posted positive results from a dose-ranging Phase 2B trial of dupilumab for the treatment of atopic dermatitis (AD).
  5. Purdue Pharma's HYD Pain Drug Receives FDA Priority Review 7/10/2014
    The U.S. Food and Drug Administration (FDA) has granted Priority Review to Purdue Pharma’s once-daily hydrocodone bitartrate tablet (HYD) with abuse-deterrent properties.
  6. Lilly And Yabao Ink Agreement To Co-Develop Diabetes Therapy 7/10/2014
    Chinese pharmaceutical company Yabao Pharmaceutical and Eli Lilly announced that they have entered into a strategic partnership to co-develop Lilly’s lead diabetes treatment.
  7. Novartis Begins Flu Vaccine Shipments To U.S. For 2014-2015 Season 7/8/2014
    Last week, Swiss pharmaceutical company Novartis announced that it has initiated shipment of its seasonal influenza vaccines to the U.S. market for the 2014-2015 flu season. The company said it plans to ship a minimum of 30 million doses of its vaccines Fluvirin and Flucelvax.
  8. Bayer Allies With University Of Oxford In Gynecological Therapies 7/8/2014
    Bayer announced that it has entered into partnership with the University of Oxford for the development of new gynecological therapies, particularly in the area of endometriosis and uterine fibroids.
  9. Roche's Genentech To Acquire Seragon Pharmaceuticals 7/3/2014
    Roche announced that Roche Group member Genentech has signed into a definitive agreement to acquire privately-held biotech firm Seragon Pharmaceuticals and its Phase I program which is currently developing a new approach for breast cancer.
  10. Jazz To Acquire Rights To Sigma-Tau's Defibrotide 7/3/2014
    Jazz Pharmaceuticals announced that it has signed into a definitive agreement to acquire defibrotide from Sigma-Tau Pharmaceuticals. Jazz will accomplish the transaction through its subsidiary Gentium, which it acquired earlier this year, and the rights will be applicable in the Americas and in the U.S.